Past, present, and future:: a 7-year update of Viagra® (sildenafil citrate)

被引:67
作者
Jackson, G
Gillies, H
Osterloh, I
机构
[1] Guys & St Thomas Hosp Trust, London, England
[2] Pfizer Global Res & Dev, Sandwich, Kent, England
关键词
Viagra; sildenafil; erectile dysfunction; review; update;
D O I
10.1111/j.1368-5031.2005.00578.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
More than 30 million men are estimated to have erectile dysfunction (ED) in the United States (Feldman et al. J Urol 1994;151: 54-61). Worldwide, ED is estimated to affect more than 150 million men, and that number is expected to exceed 300 million men by the year 2025 (Aytac et al. BJU Int 1999;84: 50-6). The prevalence of ED ranges from 7% in men aged 18-29 years (Laumann et al. JAMA 1999;281: 537-44) to 85% in men aged 76-85 years. In addition, a recent report showed that 68% of patients with ED aged 18 years and older have at least one comorbid diagnosis of hypertension, hyperlipidaemia, diabetes or depression (Seftel et al. J Urol 2004;171: 2341-5), and research suggests that ED may be an early indicator of systemic vascular disease (Kaiser et al. J Am Coll Cardiol 2004;43: 179-84). Viagra((R)) (sildenafil citrate), the first-in-class phosphodiesterase type 5 (PDE5) inhibitor, was introduced in 1998 for the treatment of ED (Boolell et al. Br J Urol 1996;78: 257-61; Boolell et al. Int J Impot Res 1996;8: 47-52). In the 7 years since its market launch, more than 750,000 physicians have prescribed sildenafil to more than 23 million men, helping establish an excellent safety and efficacy record. Clinical studies have demonstrated that sildenafil successfully treats ED of varied organic, psychogenic or mixed aetiology, and is effective in men with ED and comorbidities such as hypertension, hyperlipidaemia, diabetes or depression. Sildenafil was a breakthrough medication that addressed a previously unfulfilled medical need. The impact of sildenafil has stimulated academic, clinical and industrial research to better understand the nature of sexual function and develop better treatment and management for sexual dysfunctions such as ED. With the advent of other erectogenic therapies for the treatment of ED, this 7-year update will focus on the unique history and development of sildenafil, its current use and applications and its future directions and indications. Special emphasis is placed on the impact of sildenafil on our understanding of sexual health and on the extensive safety and efficacy data that have been amassed from numerous clinical trials.
引用
收藏
页码:680 / 691
页数:12
相关论文
共 128 条
[1]   Preclinical safety profile of sildenafil [J].
Abbott, D ;
Comby, P ;
Charuel, C ;
Graepel, P ;
Hanton, G ;
Leblanc, B ;
Lodola, A ;
Longeart, L ;
Paulus, G ;
Peters, C ;
Stadler, J .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2004, 16 (06) :498-504
[2]   Quality of life and erectile dysfunction [J].
Althof, SE .
UROLOGY, 2002, 59 (06) :803-810
[3]   Treatment responsiveness of the self-esteem and relationship questionnaire in erectile dysfunction [J].
Althof, SE ;
Cappelleri, JC ;
Shpilsky, A ;
Stecher, V ;
Diuguid, C ;
Sweeney, M ;
Duttagupta, S .
UROLOGY, 2003, 61 (05) :888-892
[4]   Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease - A Randomized crossover trial [J].
Arruda-Olson, AM ;
Mahoney, DW ;
Nehra, A ;
Leckel, M ;
Pellikka, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (06) :719-725
[5]   Fluvoxamine-induced erectile dysfunction responding to sildenafil [J].
Balon, R .
JOURNAL OF SEX & MARITAL THERAPY, 1998, 24 (04) :313-317
[6]  
Balon R, 1999, J SEX MARITAL THER, V25, P259
[7]   Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients [J].
Barrou, B ;
Cuzin, B ;
Malavaud, B ;
Petit, J ;
Pariente, JL ;
Buehler, M ;
Cormier, L ;
Benoit, G ;
Costa, P .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (02) :411-417
[8]   Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder [J].
Basson, R ;
McInnes, R ;
Smith, MD ;
Hodgson, G ;
Koppiker, N .
JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2002, 11 (04) :367-377
[9]  
*BAYER PHARM CORP, 2003, LEVITRA FULL PRESCR
[10]   Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: A double-blind, placebo controlled study [J].
Berman, JR ;
Berman, LA ;
Toler, SM ;
Gill, J ;
Haughie, S .
JOURNAL OF UROLOGY, 2003, 170 (06) :2333-2338